Ardea To Present Data On Lead HIV Candidate, RDEA806, At ICAAC/IDSA Joint Meeting

Ardea Biosciences, Inc. (Nasdaq: RDEA) announced that data will be presented on RDEA806, the Company’s novel investigational non-nucleoside reverse transcriptase inhibitor (NNRTI) for patients with human immunodeficiency virus (HIV) at the 48th Annual ICAAC/IDSA 46th Annual Meeting in Washington, DC on October 25-28, 2008. Dr.

More: continued here

Filed under: HIV / AIDS on July 31st, 2008